Trials / Completed
CompletedNCT05285904
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 107 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, observational study carried out in Switzerland that aims to describe the effects of Ofatumumab in a setting of routine medical care.
Detailed description
This non-interventional study will observe the effect of Ofatumumab treatment compared to the standard of care (SoC) arm of a closely monitored phase-IIIb study (STHENOS-COMB157G3301) in MS patients in a real-world setting in Switzerland over an observational period of 12 month.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Ofatumumab | Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab, that have started before inclusion of the patient into the study will be enrolled. |
Timeline
- Start date
- 2022-05-12
- Primary completion
- 2026-02-04
- Completion
- 2026-02-04
- First posted
- 2022-03-18
- Last updated
- 2026-04-14
Locations
13 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT05285904. Inclusion in this directory is not an endorsement.